Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
ACRX [NASD]
AcelRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.04 Insider Own0.20% Shs Outstand43.71M Perf Week-4.27%
Market Cap284.12M Forward P/E- EPS next Y-1.04 Insider Trans7.37% Shs Float42.99M Perf Month-2.26%
Income-1.80M PEG- EPS next Q-0.30 Inst Own81.60% Short Float19.17% Perf Quarter-2.99%
Sales32.60M P/S8.72 EPS this Y60.90% Inst Trans-4.55% Short Ratio12.39 Perf Half Y-32.57%
Book/sh1.36 P/B4.78 EPS next Y-9.50% ROA-1.70% Target Price10.33 Perf Year-19.95%
Cash/sh1.96 P/C3.32 EPS next 5Y- ROE-2.70% 52W Range5.22 - 13.64 Perf YTD-42.53%
Dividend- P/FCF- EPS past 5Y11.10% ROI-7.60% 52W High-52.35% Beta1.92
Dividend %- Quick Ratio8.30 Sales past 5Y- Gross Margin- 52W Low24.52% ATR0.43
Employees50 Current Ratio8.30 Sales Q/Q860.00% Oper. Margin-18.10% RSI (14)47.62 Volatility4.66% 6.18%
OptionableYes Debt/Eq0.42 EPS Q/Q107.70% Profit Margin-5.20% Rel Volume0.51 Prev Close6.62
ShortableYes LT Debt/Eq0.35 EarningsNov 10 AMC Payout- Avg Volume665.27K Price6.50
Recom2.20 SMA20-1.73% SMA50-0.49% SMA200-28.04% Volume337,825 Change-1.81%
Nov-06-14Downgrade Mizuho Buy → Neutral $15 → $6
Sep-26-14Downgrade ROTH Capital Buy → Neutral
Jul-28-14Reiterated RBC Capital Mkts Outperform $15 → $12
Jul-28-14Reiterated Mizuho Buy $20 → $15
Jul-28-14Downgrade Canaccord Genuity Buy → Hold
Apr-17-14Initiated Canaccord Genuity Buy $16
Jan-07-14Initiated RBC Capital Mkts Outperform $15
Dec-19-13Reiterated Mizuho Buy $18 → $20
Dec-17-13Reiterated MLV & Co Buy $15 → $16.50
Jul-17-13Reiterated Mizuho Neutral $13 → $18
Feb-04-13Initiated MLV & Co Buy $13
Jan-30-13Initiated Mizuho Buy $13
Oct-10-12Resumed Canaccord Genuity Buy $8
May-26-11Initiated Canaccord Genuity Buy $6
Nov-21-14 06:47PM  EQUITY ALERT: Rosen Law Firm P.A. Reminds AcelRx Pharmaceuticals, Inc. Investors of Important December 1, 2014 Class Action Deadline- ACRX GlobeNewswire
Nov-20-14 10:32AM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Business Wire
08:16AM  Zacks Rank #1 Additions for Thursday Zacks
07:00AM  AcelRx Pharmaceuticals to Participate in Four Upcoming Investor Events PR Newswire
Nov-19-14 09:42PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit Business Wire
Nov-18-14 01:04PM  ACELRX PHARMACEUTICALS INC Financials EDGAR Online Financials
Nov-17-14 06:48PM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014 Business Wire
Nov-13-14 04:16PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
07:00AM  AcelRx Pharmaceuticals Announces Zalviso Sublingual Sufentanil Data Presentation At The American Society Of Regional Anesthesia And Pain Medicine Meeting PR Newswire
Nov-12-14 07:09PM  10-Q for AcelRx Pharmaceuticals, Inc. Company Spotlight
09:04AM  AcelRx Pharmaceuticals (ACRX) Upgraded From Sell to Hold at TheStreet
Nov-11-14 12:00PM  AcelRx Pharmaceuticals (ACRX) Stock Rises After Third-Quarter Earnings Report at TheStreet +14.93%
08:14AM  Zacks Rank #1 Additions for Tuesday Zacks
06:17AM  ArQule (ARQL) Catches Eye: Stock Jumps 10.4% Zacks
05:44AM  Regulus Slumps: RGLS Falls 5.3% in Session Zacks
Nov-10-14 06:30PM  AcelRx Pharmaceuticals posts 3Q profit AP
05:12PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or EDGAR Online
04:01PM  AcelRx Pharmaceuticals Reports Third Quarter 2014 Financial Results PR Newswire
07:07AM  Q3 2014 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close CCBN
07:00AM  AcelRx Pharmaceuticals Receives International Standards Organization (ISO) 13485:2003 Certification of its Quality Management System PR Newswire
Nov-07-14 07:00AM  AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events PR Newswire +7.28%
Nov-06-14 03:34PM  INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Business Wire -9.34%
07:00AM  AcelRx Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Monday, November 10, 2014 PR Newswire
06:14AM  AcelRx downgraded by Mizuho Briefing.com
Nov-05-14 04:00PM  Acelrx Pharmaceuticals Announces Management Change PR Newswire -5.48%
Oct-31-14 05:05PM  INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $50,000 Investing in AcelRx Pharmaceuticals, Inc. (ACRX) to Contact the Firm GlobeNewswire
Oct-29-14 01:04PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in AcelRx Pharmaceuticals, Inc. to Contact Brower Piven Before the December 1, 2014 Lead Plaintiff Deadline in Class Action Lawsuit - GlobeNewswire
07:53AM  Can The Uptrend Continue for AcelRx Pharmaceuticals (ACRX)? Zacks
Oct-27-14 04:27PM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014 -- ACRX Marketwired
07:00AM  AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentations At The American College Of Surgeons Meeting PR Newswire
Oct-22-14 02:40PM  EQUITY ALERT: Rosen Law Firm P.A. Reminds AcelRx Pharmaceuticals, Inc. Investors of Important Class Action Deadline - ACRX GlobeNewswire
07:00AM  AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results PR Newswire
Oct-20-14 12:42PM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014 -- ACRX GlobeNewswire
Oct-16-14 07:00AM  AcelRx Pharmaceuticals Provides Update on its Patent Portfolio for Zalviso and its Proprietary Platform Technologies PR Newswire +6.83%
Oct-15-14 08:26PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit Business Wire +6.17%
Oct-10-14 07:30PM  Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against AcelRx Pharmaceuticals, Inc. -- ACRX GlobeNewswire
06:37PM  INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $50,000 Investing in AcelRx Pharmaceuticals, Inc. (ACRX) to Contact the Firm Marketwired
07:00AM  AcelRx Pharmaceuticals Announces Multiple Sublingual Sufentanil Data Presentations At The American Society Of Anesthesiologists Meeting PR Newswire
Oct-08-14 01:52PM  Robbins Arroyo LLP: AcelRx Pharmaceuticals, Inc. (ACRX) Misled Shareholders According to a Recently Filed Class Action GlobeNewswire
Oct-07-14 08:35PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in AcelRx Pharmaceuticals, Inc. to Contact Brower Piven Before the December 1, 2014 Lead Plaintiff Deadline in Class Action Lawsuit - GlobeNewswire
08:00PM  Harwood Feffer LLP Announces Investigation of AcelRx Pharmaceuticals, Inc. PR Newswire
06:31PM  Lifshitz & Miller Law Firm Announces Investigation of AcelRx Pharmaceuticals, Inc., Ambit Biosciences, Athlon Energy Inc., LipoScience, Inc., Simplicity Bancorp, Inc., and TIBCO Software Inc. PR Newswire
11:10AM  AcelRx Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors Business Wire
Oct-06-14 05:54PM  Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Marketwired
02:21PM  EQUITY ALERT: The Rosen Law Firm P.A. Announced Filing of Securities Class Action Against AcelRx Pharmaceuticals, Inc. - ACRX GlobeNewswire
02:08PM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014 -- ACRX GlobeNewswire
07:00AM  Sufentanil sublingual tablet system study results to be presented at the International Association for the Study of Pain Meeting PR Newswire
Oct-03-14 07:15PM  INVESTOR ALERT: Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Announced by Law Offices of Howard G. Smith Business Wire
04:00PM  INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In AcelRx Pharmaceuticals, Inc. (ACRX) To Contact The Firm PR Newswire
Oct-02-14 10:32AM  INVESTOR ALERT: Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Filed By Glancy Binkow & Goldberg LLP Business Wire
Sep-29-14 02:45PM  SHAREHOLDER ALERT: Investigation on Behalf of AcelRx Pharmaceuticals, Inc. Investors Announced by Law Offices of Howard G. Smith Business Wire +9.06%
10:40AM  INVESTOR ALERT: Investigation on Behalf of AcelRx Pharmaceuticals, Inc. Shareholders Announced by Glancy Binkow & Goldberg LLP Business Wire
Sep-26-14 04:35PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online -19.49%
03:23PM  Why AcelRx Pharmaceuticals (ACRX) Stock Hit a One-Year Low Today at TheStreet
11:22AM  Midday movers: Apple, RadioShack, Shutterfly & more at CNBC
09:34AM  [$$] AcelRx Shares Slide on FDA Delay at The Wall Street Journal
07:00AM  AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso PR Newswire
Sep-10-14 07:00AM  AcelRx Announces Publication of Manuscript Analyzing Cost of Intravenous Patient-Controlled Analgesia with Opioids PR Newswire
Sep-04-14 07:00AM  AcelRx Announces Publication of Sufentanil Sublingual Tablet System vs. Intravenous Patient-Controlled Analgesia with Morphine for Postoperative Pain Study Results PR Newswire
Aug-27-14 07:00AM  AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events PR Newswire
Aug-26-14 02:22PM  The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks at TheStreet
Aug-11-14 05:01PM  ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
04:00PM  AcelRx Pharmaceuticals Reports Second Quarter 2014 Financial Results PR Newswire
07:07AM  Q2 2014 AcelRx Pharmaceuticals, Inc. Earnings Release - After Market Close CCBN
Aug-08-14 07:00AM  AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events PR Newswire
Aug-07-14 07:00AM  AcelRx Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Monday, August 11th, 2014. PR Newswire
Aug-01-14 08:16AM  AcelRx Pharmaceuticals (ACRX) Soars: Stock Adds 6.8% in Session Zacks
07:00AM  4 Biotech Stocks Under $10 to Trade for Breakouts at TheStreet
Jul-29-14 06:03PM  Nasdaq stocks posting largest percentage decreases AP
10:20AM  Today's Dead Cat Bounce Stock: AcelRx Pharmaceuticals (ACRX) at TheStreet
08:40AM  Top Analyst Upgrades and Downgrades: AcelRx, Alcoa, Costco, Lululemon, Walmart, Trulia and More at 24/7 Wall St.
Jul-28-14 04:32PM  U.S. Stocks Little Changed on Mergers, Data Before Fed Bloomberg -41.00%
04:15PM  Dow, S&P 500 inch up, while Nasdaq, Russell 2000 slip: stock market live blog recap at MarketWatch
04:05PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
02:35PM  AcelRx Pharma Plunges After FDA Rejects Device at Investor's Business Daily
10:07AM  Why AcelRx Pharmaceuticals (ACRX) Stock Is Plummeting Today at TheStreet
09:44AM  FDA Rejects AcelRx Painkiller Dispensing Device (Update) at TheStreet
09:35AM  [video] Mon., July 28: Family Dollar Among Stocks to Watch at MarketWatch
09:15AM  AcelRX Selling Off Sharply On FDA Reexamination Benzinga
08:48AM  AcelRx stock plunges after FDA rejects pain drug device Reuters
Jul-27-14 01:25PM  FDA issues Complete Response Letter for AcelRx NDA for Zalviso at theflyonthewall.com
Jul-25-14 09:59PM  AcelRx Pharmaceuticals Receives Complete Response Letter from FDA for New Drug Application for Zalviso PR Newswire +5.97%
02:52PM  Why AcelRx Pharmaceuticals Inc Stock Boomed at Motley Fool
Jul-24-14 11:49PM  AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso PR Newswire
Jul-23-14 09:01AM  Edelman's Perceptive Advisors Buying Amicus Therapeutics Ahead Of Phase III Data Release at Seeking Alpha +6.73%
07:52AM  Shorting AcelRx Into PDUFA: A Risky Proposition at Seeking Alpha
Jul-21-14 01:19PM  Nasdaq stocks posting largest percentage increases AP
07:06AM  AcelRx Pharmaceuticals (ACRX) Jumps: Stock Adds 11.7% in Session Zacks
Jul-07-14 10:13AM  AcelRx's Upcoming PDUFA And Trade Recommendations at Seeking Alpha
03:00AM  AcelRx and Grunenthal Announce Submission of European Marketing Authorization Application for ZALVISO PR Newswire
Jul-03-14 09:04AM  5 Stocks Spiking on Unusual Volume at TheStreet
Jul-02-14 08:30AM  AcelRx Should Trend Higher As FDA Approval Is Likely At End Of This Month at Seeking Alpha
Jun-19-14 07:00AM  AcelRx Pharmaceuticals to Present at the JMP Securities Healthcare Conference PR Newswire -5.10%
Jun-17-14 09:47AM  AcelRx Pharmaceuticals (ACRX) Jumps: Stock Rises 9.0% Zacks
Jun-16-14 04:35PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Of EDGAR Online +8.95%
Jun-03-14 07:00AM  Results of Cost Analysis Study Presented at ISPOR Meeting Identify Intravenous Patient-Controlled Analgesia (IV PCA) Costs of $200 to $240 for Two Days of Post-Surgical Pain Management PR Newswire
Jun-02-14 04:31PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
04:13PM  AcelRx Pharmaceuticals Announces The Departure Of David Chung PR Newswire
May-29-14 08:00AM  AcelRx Pharmaceuticals to Present at the Jefferies Global Healthcare Conference PR Newswire
06:09AM  AcelRx management to meet with Piper Jaffray at theflyonthewall.com
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain (BTP). Its principal product candidate is Zalviso, an investigational pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in adult patients in the hospital setting. The company is also developing ARX-04, a Sufentanil Single-Dose NanoTab, which has completed Phase II clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as on the battlefield, in the emergency room, or in ambulatory care facilities. In addition, its product candidate pipeline consists of ARX-02, a Sufentanil NanoTab pain management system, which has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain (BTP); and ARX-03, a Sufentanil/Triazolam NanoTab, a Phase II clinical trials completed product designed to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WAN MARK ADirectorMar 10Sale12.36835,32710,324,642126,153Mar 11 02:34 PM
WAN MARK ADirectorMar 07Sale12.30164,6732,025,400137,403Mar 11 02:34 PM